Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 54Stomach Neoplasms 42Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 21Esophageal Squamous Cell Carcinoma 15Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 10Esophageal Neoplasms 9Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 5Liver Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Colonic Neoplasms 3Carcinoma 3Breast Neoplasms 3Turcot syndrome 2Thyroid Neoplasms 2Spinocerebellar Degenerations 2Sarcoma 2Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 21Capecitabine 20Fluorouracil 11Leucovorin 9Irinotecan 9130-nm albumin-bound paclitaxel 8durvalumab 6Taxes 5Radiotherapy 5Platinum 4Immunohistochemistry 4Erlotinib Hydrochloride 4Docetaxel 4Carboplatin 4Bevacizumab 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4trifluridine tipiracil drug combination 3Trastuzumab 3Sorafenib 3Observation 3Epirubicin 3Drug Therapy 3tremelimumab 2toripalimab 2regorafenib 2pembrolizumab 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gallbladder Neoplasms × sintilimab × Clear all
NCT05757336 2023-03-07

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Fudan University

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡